# Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT

> **NCT06265883** · — · COMPLETED · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 205 (actual)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** Len+DEB-TACE+HAIC
- **PROCEDURE:** Len+DEB-TACE

## Key facts

- **NCT ID:** NCT06265883
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265883, "Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06265883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*